Previa Medical

Founded 2020
Employees 4+
Primary contact
38, Rue Denuziere
69002 Lyon
France
The company has developed an AI tech called SEPSI-SCORE, which is capable of forecasting pathologies. Compatible with all major EHR systems using FHIR technology, it analyzes the data of thousands of patients in real time and accurately identifies the complication risks. Certified in 2021, SEPSI-SCORE can alert up to 48 hours before the first symptoms of sepsis. As a result, Previa Medical enables healthcare professionals to trigger treatment protocols earlier, reducing lengths of stay and saving lives.
Founded 2020
Employees 4+
Primary contact
38, Rue Denuziere
69002 Lyon
France

Funding 💰

Total €2.1M
Last round 🔗 €2.1M
Seed
February 16, 2023.
Select investors Bpifrance, Kreaxi, M2 Care, Capital Croissance, Holding Seraip, BNP Paribas Développement, Veymont Participations

Key people 🧑‍🤝‍🧑

Highlights

  • Solving a real problem: Sepsis is one of the leading causes of hospital deaths worldwide, with a 30-day mortality rate of 20 to 30%. Previa Medical's SEPSI-SCORE, therefore, provides a much-needed solution to a major global public health issue.
  • Compatible: Previa Medical's solution is compatible with the major EHR systems thanks to FHIR support. When implemented, SEPSI-SCORE can analyze in real time laboratory results, vital signs, and medical history.
  • Certified: SEPSI-SCORE was certified as a medical device in 2021 for the identification of risks of sepsis using a predictive algorithm and the latest machine learning techniques.

Video ▶️

Quotes 💬

The management team's approach, as well as its decision to develop a solution for sepsis, a complex disease, have impressed me most about the Previa Medical project. There is a real medical need to improve monitoring, prediction and diagnosis. This start-up's solution is completely agnostic and can be used for any patient who might be at risk of developing sepsis.
Sandra Dubos, investment director at Kreaxi 🔗
M2care's decision to invest in Previa Medical was based on its highly skilled founders and their vision to develop viable applications for predictive medicine that will benefit patients and healthcare professionals alike. Our team of entrepreneurs in residence are convinced this solution has real potential; they are committed to de-risking the project's next clinical, commercial and financial milestones, while also accelerating its growth and strengthening its operational team.
Florence Thueux, president and managing director of M2care 🔗
We decided to invest in this dynamic start-up because it operates in the healthcare sector and uses AI in its technology. We have shareholders in both these areas who have valuable expertise that they can bring to the Previa Medical team.
Aymeri Chomel, president of Veymont Participations 🔗
Last update: March 8, 2023